MAM
PGNX

Meeder Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Meeder Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-720
Closed -$3K – 2685
2020
Q1 		$3K Sell
720
-13,590
-95% -$58.6K ﹤0.01% 2037
2019
Q4 		$73K Buy
14,310
+13,721
+2,330% +$72.6K ﹤0.01% 900
2019
Q3 		$3K Sell
589
-2,565
-81% -$12.8K ﹤0.01% 1922
2019
Q2 		$20K Buy
3,154
+2,569
+439% +$12.4K ﹤0.01% 1247
2019
Q1 		$3K Sell
585
-790
-57% -$3.57K ﹤0.01% 1526
2018
Q4 		$6K Sell
1,375
-2,806
-67% -$14.3K ﹤0.01% 1389
2018
Q3 		$26K Buy
4,181
+3,584
+600% +$27.5K ﹤0.01% 965
2018
Q2 		$4.8K Sell
597
-232
-28% -$1.77K ﹤0.01% 1286
2018
Q1 		$6K Sell
829
-118
-12% -$785 ﹤0.01% 1200
2017
Q4 		$6K Buy
947
+202
+27% +$1.23K ﹤0.01% 1291
2017
Q3 		$5K Buy
745
+3
+0.4% +$19 ﹤0.01% 1299
2017
Q2 		$5K Buy
742
+265
+56% +$1.96K ﹤0.01% 1226
2017
Q1 		$5K Sell
477
-162
-25% -$1.62K ﹤0.01% 1122
2016
Q4 		$6K Buy
+639
New +$4.72K ﹤0.01% 846

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Meeder Asset Management's PGNX Position: Q2 2020 in Review

Meeder Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 720 shares — an estimated $3K sold.

Meeder Asset Management first reported a position in PGNX in Q4 2016 and held it in 14 quarters. The position peaked at $73K in Q4 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Meeder Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 720 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $3K.
  • Meeder Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 14 quarters.
  • Meeder Asset Management's Progenics Pharmaceuticals Inc position peaked at $73K in Q4 2019.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.